Section of Nephrology
Associate Professor of Medicine
Associate Director,Nephrology Fellowship Program; Medical Director, Stony Island Dialysis facility
Referring Physician Access Line: 1-877-DOM-2730
|Residency||1994||Lutheran General Hospital||Internal Medicine
|Fellowship||1996||University of Illinois at Chicago||Nephrology
Dr. Stankus’ research interests focus on various aspects of end stage kidney disease, including current treatment methods for secondary hyperparathyroidism, prevention of bone and cardiac disease, new approaches in improving longevity of dialysis vascular access and prevention of systemic Staphylococcal infections in patients on hemodialysis. She also fosters a special interest in geriatric aspects of nephrology.
Care of patients with end stage kidney disease on hemodialysis and general consultative nephrology.
- E. Lazar, K. Hebert, T. Poma, N. Stankus. Cinacalcet And Paricalcitol Titration Protocol Improves Long Term Treatment Outcomes In Secondary Hyperparathyroidism. Am J Nephrol 12;27(3):274-278, 2007
- N. Stankus, D. Gillen, M. Hammes, E. Worcester. African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III. Urol Res 35(2):83-7, 2007
- E. Lazar, N. Stankus. Cinacalcet- Induced Hungry Bone Syndrome. Semin Dial 20(1): 83–85, 2007
- N. Stankus, E. Worcester, M. Hammes, F. L Coe. Evidence against a contribution of conventional urine risk factors to de novo ESRD renal stones. Nephrol Dial Transplant. 21(3):701-6, 2006